Jordi Bruix, MD, PhD, is professor of medicine at the University of Barcelona and director of the Barcelona Clinic Liver Cancer (BCLC) Group within the Liver Unit at the Hospital Clinic of Barcelona, Spain.
Prof. Bruix has been the principal investigator of studies and clinical trials that have changed practice in the field of hepatocellular carcinoma (HCC), including development of diagnostic criteria and prognostic models and establishment of chemoembolization and sorafenib as conventional therapy. He developed the BCLC staging and treatment strategy that has been endorsed by several international scientific associations to guide management of patients with HCC. He has also authored more than 200 original investigations and led the development of Evidence-Based Practice Guidelines for Hepatocellular Carcinoma at EASL, AASLD, and the World Gastroenterology Organisation (WGO). He is Director of the Spanish Network for Research in Hepatic and Digestive Diseases within the Spanish National Institute of Health since 2015.
Prof. Bruix is a member of the European Association for the Study of the Liver (EASL) where he was Secretary General from 2001 to 2005, and the American Association for the Study of Liver Diseases (AASLD). He founded the International Liver Cancer Association (ILCA) and was its president from 2006 to 2009. He has been associate editor of Journal of Hepatology, Liver Transplantation, Hepatology and Seminars in Liver Disease, and now is Co- Editor in Chief for this last one.